Mycoplasma genitalium is an important and emerging agent of sexually transmitted infection in females and males, carrying the potential for postinfection genital tract sequelae. Past efforts to identify this organism on a routine basis, which were problematic due to the fastidious nature of the bacterium and its antigenic intricacies, have recently become supplemented by molecular diagnostics. A number of these assays are available commercially. This minireview describes the format and performance indices of a number of M. genitalium DNA-and RNA-based amplification assays; many of these assays have contributed to an improved clinical and epidemiologic understanding of this organism.
I n 1981, the first report of recovery and identification of Mycoplasma genitalium, the smallest free-living microorganism capable of reproduction, was published (1) . However, the fastidious nature of this intracellular bacterium significantly limits its ability to be cultivated in an in vitro setting (2) . Attempts at serologic diagnosis have been confounded by antigenic variation of M. genitalium (3) and immunogenic analogs observed in other Mollicutes, such as Mycoplasma pneumoniae (4) . These paradigms are unfortunate because of the long-standing association of M. genitalium with nongonococcal and nonchlamydial urethritis in males (2) and an emerging collection of literature implicating the organism in cervicitis, pelvic inflammatory disease, preterm birth, and spontaneous abortion (5) . Other investigators have reported promotion of HIV acquisition (6) and shedding (7) by antecedent M. genitalium infection.
Initial efforts to alleviate the gap in laboratory diagnosis of M. genitalium infection involved molecular assays performed in research settings. Hooton et al. (8) utilized a radiometric dot hybridization assay to detect M. genitalium DNA from 30 of 203 male urethral swabs. Jensen et al. (9) targeted the M. genitalium 140-kDa adhesion protein gene (MgPa) in 150 urogenital specimens that were originally collected for Chlamydia trachomatis culture. Restriction digestion and hybridization identified the target in 6.7% of specimens. MgPa nomenclature will be used in this paper in reference to genetic derivatives of the adhesion protein gene frequently used in assay development.
In an attempt to highlight M. genitalium diagnostic advancements, a PubMed primary literature search (U.S. National Library of Medicine and the National Institutes of Health), conducted on 8 May 2017, selected 417 in-print English language citations from the years 1991 to 2017 ( Fig. 1 ). Ten additional manuscripts had a status of electronic publication ahead of print. Nearly 27% of the aforementioned publications entered the literature between 2006 and 2011, perhaps coinciding with some of the first commercial attempts at assay development; over 41% have been published since 2012, which may be in line with increasing reports of clinical macrolide treatment failure and concomitant development of molecular assays to alert clinicians to this possibility. This brief commentary, with a focus largely on literature published within the past 2 years, provides an update on M. genitalium molecular diagnostics and suggests that these assays may soon become commonplace for the clinical microbiologist.
COMMERCIALLY DEVELOPED DNA AMPLIFICATION ASSAYS
A number of commercially produced M. genitalium DNA amplification modalities have been described. M. genitalium-specific dual-priming oligonucleotide primers have been incorporated into a multiplex PCR assay for six sexually transmitted infection (STI) agents, with subsequent detection of end products via auto-capillary electrophoresis (Seeplex STD6 ACE; Seegene, Seoul, South Korea). One evaluation (10), performed on 739 urogenital specimens, was limited by utilization of a monoplex PCR (using the same primer sets) to confirm positive results and by M. genitalium DNA being detected from only two specimens. Kweon The LightMix Mycoplasma genitalium kit (TIB Molbiol, Berlin, Germany) is a commercially available real-time PCR assay that requires nucleic acid extraction apart from the kit. The assay, targeting a 224-bp gap sequence, was applied to the cobas z 480 analyzer (14) . In a study of 104 archived urogenital DNA extracts, kit-provided internal control was amplified in all instances. When compared to a research M. genitalium PCR reference standard, sensitivity and specificity of the LightMix Mycoplasma genitalium kit were 92.6% and 100%, respectively.
A number of M. genitalium DNA amplification assays have received Conformité Européene in vitro diagnostic (CE) marking. The Bio-Rad Dx CT/NG/MG assay (Bio-Rad, Marnes-la-Coquette, France) is a multiplex PCR assay that incorporates an internal control and provides a lysis reagent for manual nucleic acid extraction. The assay is CE-marked for performance on vaginal, cervical, and urethral swabs as well as female and male first-void urine samples. M. genitalium MgPa amplification and detection occur in manufacturer-provided instrumentation. When compared to research MgPa PCR results, the Bio-Rad Dx CT/NG/MG assay exhibited 100% sensitivity from 658 female and male urogenital specimens acquired from 453 French STI clinic patients (15) . However, just 11 specimens had detectable M. genitalium DNA using the evaluated method, one of which (vaginal swab collection) was classified as a false-positive result.
The Hyplex STD Mycoplasma test system (Amplex BioSystems, Lich, Germany) is a CE-marked multiplex PCR for detection of M. genitalium, M. hominis, U. urealyticum, and U. parvum. A prototype of this assay was reported to have 87% sensitivity and 96% specificity for detection of M. genitalium MgPa (16). Khatib et al. (17) utilized this assay (in concert with commercial RNA methods for C. trachomatis, N. gonorrhoeae, and Trichomonas vaginalis detection) for assessment of symptomatic males in the United Kingdom. M. genitalium DNA was detected in 11 of 83 (13.3%) first-void urine specimens and was the only agent detected in six of those specimens. All positive findings were confirmed by research M. genitalium PCR. A total of 42.2% of specimens in this report had no detectable nucleic acid specific to C. trachomatis, N. gonorrhoeae, T. vaginalis, M. genitalium, or U. urealyticum.
The AmpliSens N. gonorrhoeae/C. trachomatis/M. genitalium/T. vaginalis-Multiprime-FRT assay (InterLabScience, Moscow, Russia) is a CE-marked real-time PCR assay containing an internal control that requires independent nucleic acid extraction. Amplification and detection of M. genitalium gyrB is facilitated by an open-channel platform. Rumyantseva et al. (18) evaluated this assay using 1,261 frozen specimens originally collected from Swedish STI clinic attendees in transport medium specific to a commercial RNA amplification system. AmpliSens M. genitalium data were compared to those of two reference commercial RNA amplification assays. Overall AmpliSens sensitivity was 81.9%, with a range of 76.5% to 84.8% among vaginal specimens and first-void urine samples from both genders. No false-positive results were derived from the AmpliSens assessment; 59 patients yielded detectable M. genitalium RNA within this study.
Le Roy Fast-track diagnostics (Sliema, Malta) produces a number of CE-marked multiplex qualitative PCR assays for STI agents that allow for M. genitalium MgPa detection from first-void urine, genital, and rectal collections. The assays include an internal control and require additional instruments for DNA extraction and target amplification/detection. However, a paucity of peer-reviewed studies exists comparing assay performance to other molecular diagnostic modalities. Gossé et al. (21) adapted the FTD Urethritis basic assay to a quantitative PCR format to investigate a test-of-cure paradigm for azithromycin therapy. Using daily first-void urine specimens over the course of 14 days, the authors concluded that fluctuations in bacterial counts hypothetically result in falsenegative tests of cure. Consequently, the authors advocated M. genitalium mutation analysis at time of organism detection as an optimal means of addressing therapeutic options.
The CE-marked ResistancePlus MG kit (SpeeDx, Sydney, Australia) utilizes PlexZyme/ PlexPrime technology for real-time quantitative PCR (qPCR) detection of M. genitalium on an open-channel platform. The multiplex assay includes an internal control and can identify mutations in 23S rRNA sequences encoding macrolide resistance. An assay prototype was described by Tabrizi et al. (22) using an Australian cohort of 254 M. genitalium-infected patients during clinical follow-up. In a collection of 400 urine/ urethral swab, cervical/vaginal swab, and anal swab specimens, the evaluated assay achieved 99.0% concordance in comparison to a research 16S rRNA gene qPCR reference. Four noted discrepant specimens each contained a low M. genitalium copy number. With respect to organism detection by the ResistancePlus MG kit, a retrospective assessment of 206 urogenital specimens produced a kappa value of 0.98 when compared to a combined research PCR and S-DiaMGTV reference standard (23) . One ResistancePlus MG result was false-negative (98.9% sensitivity), and internal control amplification failure occurred at a rate of 0.48%. Taken together, this assay may be positioned to address current and future conundrums of clinical M. genitalium resistance.
COMMERCIALLY DEVELOPED RNA AMPLIFICATION ASSAYS
Over 10 years have passed since the initial formulation of RNA amplification assays specific to M. genitalium 16S rRNA using transcription-mediated amplification (TMA; Hologic, San Diego, CA). Hardick et al. (24) determined the sensitivity of research multitarget PCR (16S rRNA gene, MgPa) and TMA for M. genitalium detection to be 88.8% and 100.0%, respectively, from 286 male urine specimens. M. genitalium prevalence exceeded 13% in this U.S. STI clinic demographic. Wroblewski et al. (25) assessed 352 male urine specimens from U.S. STI clinic attendees by research MgPa PCR and TMA, reporting detection rates of 7.4% and 6.8%, respectively. A preliminary TMA investigation in females (24) yielded 96.9% sensitivity and 98.4% specificity from 321 self-collected vaginal swabs in a population with 19.6% M. genitalium prevalence. Analogous values for multitarget PCR were 93.8% and 99.2%. The other report (25) noted sensitivity values of M. genitalium TMA (relative to a standard of a patient yielding a positive research PCR or TMA result) from vaginal and cervical specimens as being 84% and 60%, respectively. Comparative values for research PCR were 91% and 53%. Prevalence rates derived from these specimen sources ranged from 9% to 14%.
Wroblewski et al. (25) introduced the prospect of alternative specimen sources for female screening. Sensitivity values of MgPa PCR and TMA assays on female first-void urine samples (relative to a standard of a patient being positive for either test) were calculated at 65% and 58%, respectively. The authors did not provide information regarding urine preservation, other than the fact that specimens were archived at Ϫ80°C prior to analysis. These data come with the additional caveat that cell walldeficient microbes, such as M. genitalium, are likely more susceptible to lytic activities or components endogenous to urine (25) . Data concerning another STI pathogen, T. vaginalis, may be extrapolated into the potential value of first-void urine samples as a noninvasive screen for M. genitalium in females using TMA. Using a molecular-resolved algorithm, Nye et al. (26) determined the sensitivity values of commercial T. vaginalis TMA on 296 first-void female urine, endocervical, and vaginal specimens to be 87.5%, 89.8%, and 96.6%, respectively. Analogous values derived from PCR were 76.1%, 80.9%, and 83.0%. These data further provide evidence for the enhanced analytical sensitivity of commercial TMA versus conventional DNA amplification methods. Potential explanations for this difference (oligonucleotide-based target capture for removal of endogenous inhibitors, differences in nucleic acid target quantity), which may further promote the value of urine screening efforts, have been discussed in a previous review (27) .
TMA-based detection of M. genitalium has subsequently been adapted to an analyte-specific reagent (ASR) format on automated analyzers. In a study of males from an STI clinic and community care settings (apart from the STI clinic) in a highprevalence U.S. STI community (28) , residual contents of 2,750 consecutive first-void urine samples, preserved in Aptima urine specimen transport tubes (Hologic) within 24 h of primary void, were subjected to M. genitalium ASR on TIGRIS automation. The M. genitalium ASR detection rate (6.84%) nearly equaled that generated by C. trachomatis TMA (6.87%) and exceeded those of N. gonorrhoeae TMA and laboratory-validated T. vaginalis TMA. M. genitalium distribution, when delineated by patient age, was similar to distributions exhibited by N. gonorrhoeae and C. trachomatis.
STI phenotype can be defined as M. genitalium, C. trachomatis, N. gonorrhoeae, and T. vaginalis distribution within a given health care encounter that yields detection of at least one STI agent. This measure essentially denotes the probability that a given agent is the etiology of the STI diagnosed during that encounter. In the aforementioned study (28) , a dichotomy of STI prevalence emerged when comparing STI phenotypes involving M. genitalium and T. vaginalis (Table 1 ). Sole detection of M. genitalium was documented in 36.5% of STI clinic visits that yielded at least one STI; this frequency was 22.0% within community care encounters (P ϭ 0.0007). Overall detection of M. genitalium STI phenotype occurred in 47.4% of STI clinic visits that generated at least one STI; that value was 29.7% within community care encounters. In contrast, while 5.3% of STI clinic visits that yielded at least one STI involved sole detection of T. vaginalis, 18.7% of community care visits that generated at least one STI demonstrated sole detection of T. vaginalis. A total of 7.1% of STI clinic encounters with at least one detectable STI agent yielded T. vaginalis, while the analogous value in community care was 21.1%.
A community-wide study (with broad demographic and acuity-of-illness coverage) in the same U.S. high-prevalence STI community assessed M. genitalium ASR using 2,478 residual female specimens submitted for routine laboratory screening of C. trachomatis, N. gonorrhoeae, and T. vaginalis (29) . The M. genitalium detection rate was 11.4% and exceeded those of the other STI agents (P Յ 0.005). Sufficient material following primary M. genitalium ASR performance allowed for repeat testing of 208 M. genitalium-positive specimens; 207 (99.5%) yielded a positive result. Furthermore, a subset of 242 specimens was subjected to M. genitalium TMA with an alternative target. A 98.8% overall concordance of results was observed, including a 99.5% concordance rate among 213 specimens that initially yielded a negative M. genitalium ASR result. Age distribution of females with detectable M. genitalium mirrored those of females infected with C. trachomatis and N. gonorrhoeae.
M. genitalium detection rates, stratified by specimen source, ranged from 10.1% (first-void urine) to 13.8% (vaginal swab). As only 138 vaginal specimens were assessed on the basis of this representative, retrospective collection, the 13.8% vaginal swab detection rate was not significantly increased over that of urine (P ϭ 0.23). The cervical swab detection rate from 1,896 specimens (11.5%) demonstrated no significant difference versus those of first-void urine and vaginal swab (P Ն 0.41). These data were limited by all specimens being collected in routine clinical practice, during which multiple patient samplings did not occur.
Nonutilization of the M. genitalium ASR would result in significant missed opportunities for STI detection. Of the 282 overall M. genitalium detections, M. genitalium was the sole STI agent detected in 203 (72.0%) of these instances ( Table 2 ). In this high-prevalence population, one specific patient demographic demonstrated a greater proclivity for this organism. When compared to highly prevalent T. vaginalis (9.0% overall detection rate), M. genitalium detection rates from inpatient obstetric/gynecologic (OB/GYN), suburban family care, urban family care, and emergency room (ER)/ urgent care settings showed little variation (P Ն 0.37) ( Table 2 ). However, the M. genitalium detection rate from 1,032 outpatient OB/GYN clinic patients (10.3%) was elevated versus that of T. vaginalis (6.4%; P ϭ 0.001). Moreover, relative to the M. genitalium sole detection paradigm, 80.2% of outpatient OB/GYN clinic patients with (30) confirmed and extended several of the findings from the previous two studies. M. genitalium and C. trachomatis prevalence rates (17.2% and 17.8%, respectively) were equally high among males. The female M. genitalium ASR detection rate (16.3%) was significantly higher than those of C. trachomatis and N. gonorrhoeae but less than that of T. vaginalis. Significant associations were made between M. genitalium detection and non-Hispanic ethnicity, African American race, younger age, and female symptomatic status. Moreover, a high frequency of single-agent infection was demonstrated.
Tabrizi et al. (31) evaluated an M. genitalium TMA assay on the automated Panther platform (Hologic) in comparison to a composite molecular standard comprised of an alternative target TMA assay, 16S rRNA gene PCR, and MgPa PCR. Sensitivity and specificity values for the CE-marked assay were 100% and 93.6%, respectively, from 1,080 urine specimens collected from a diverse clinical population with nearly 9% M. genitalium prevalence. Sensitivity values for the two PCR assays ranged from 89.1% to 91.3%. These data extend earlier findings (18, 24, 26) regarding the improved potential of STI agent detection using TMA modalities.
OUTLOOK
The field of molecular diagnostics, particularly in the last 8 to 10 years, has strived to fulfill an unmet clinical need with respect to this fastidious organism. Differences in M. genitalium prevalence exist throughout the world (references 10, 13, 15, and 18 to 20 discuss low prevalence; references 17, 24, 25, and 28 to 33 discuss high prevalence), which may influence local routine screening decisions. The possibility does exist that the lower sensitivity of DNA amplification testing may result in an underestimation of prevalence. However, concern for macrolide-resistant strains of M. genitalium may supersede some of these lower-prevalence data in providing impetus for clinical screening. Less-invasive means of specimen collection, such as first-void urine or self-collected vaginal swab options, may promote a higher screening frequency, particularly in scenarios that do not require a physical examination. Furthermore, Dize et al. (32) reported that M. genitalium ASR performed on self-collected penile-meatal swabs (investigated in a U.S. STI clinic with 14% M. genitalium prevalence) yielded performance indices equivalent to those derived from clinician-collected urethral swabs.
As clinical microbiologists encounter the increased availability of M. genitalium molecular diagnostics, including those ultimately receiving FDA clearance, additional studies will be necessary to ascertain the optimal specimen source in terms of performance characteristics and patient accessibility. Moreover, a recent report suggests that inclusion of multiple analytes and specimen source collections significantly increases detection of STI carrier status (33) . Further investigations may be necessary to indicate targeted demographics (20, (28) (29) (30) should a fully comprehensive screening approach not be advocated in a given locale. Consideration of M. genitalium molecular diagnostics within an STI screening algorithm may ultimately realize public health benefits and improved clinical management.
